A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia
Authors:
Published:
0000-00-00
DOI:
HTTPS://DOI.ORG/10.1002/ajh.27303
Keywords:
Abstract:
Source: